SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mahr AD. Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one ‘anti-neutrophil cytoplasm antibodies-associated vasculitis’ entity? APMIS Suppl 2009; 127: 417.
  • 2
    Godman GC, Churg J. Wegener's granulomatosis: pathology and review of the literature. AMA Arch Pathol 1954; 58: 53353.
  • 3
    Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67: 3938.
  • 4
    Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 3644.
  • 5
    Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 4639.
  • 6
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2005; 52: 24619.
  • 7
    Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 21808.
  • 8
    De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 67080.
  • 9
    Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005; 52: 216878.
  • 10
    Faurschou M, Mellemkjaer L, Sorensen IJ, Svalgaard Thomsen B, Dreyer L, Baslund B. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60: 118792.
  • 11
    Morgan MD, Turnbull J, Selamet U, Kaur-Hayer M, Nightingale P, Ferro CJ, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody–associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009; 60: 3493500.
  • 12
    Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109: 171823.
  • 13
    Raza K, Thambyrajah J, Townend JN, Exley AR, Hortas C, Filer A, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000; 102: 14702.
  • 14
    Schachinger V, Zeiher AM. Atherosclerosis-associated endothelial dysfunction. Z Kardiol 2000; 89 Suppl: IX/704.
  • 15
    Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 94854.
  • 16
    Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 198492.
  • 17
    Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 3107.
  • 18
    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 35161.
  • 19
    Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 6718.
  • 20
    Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 37180.
  • 21
    D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 74353.
  • 22
    Harrell F. Regression modeling strategies with applications to linear models, logistic regression, and survival analysis. 1st ed. New York: Springer; 2001.
  • 23
    Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.
  • 24
    Royston P. Multiple imputation of missing values: update. Stata J 2005; 5: 188201.
  • 25
    Royston P. Multiple imputation of missing values: update of ICE. Stata J 2005; 5: 52736.
  • 26
    Royston P. Multiple imputation of missing values. Stata J 2004; 4: 22741.
  • 27
    Archer K. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata J 2006; 6: 97105.
  • 28
    DeMaris A. Explained variance in logistic regression: a Monte Carlo study of proposed measures. Sociol Methods Res 2002; 31: 2774.
  • 29
    UCLA Academic Technology Services Statistical Consulting Group. What are pseudo R-squareds? URL: http://www.ats.ucla.edu/stat/mult_pkg/faq/general/Psuedo_RSquareds.htm.
  • 30
    Granger DN, Rodrigues SF, Yildirim A, Senchenkova EY. Microvascular responses to cardiovascular risk factors. Microcirculation 2010; 17: 192205.
  • 31
    Tanasescu C, Jurcut C, Caraiola S, Nitescu D, Copaci I, Jurcut R. Endothelial dysfunction in inflammatory rheumatic diseases. Rom J Intern Med 2009; 47: 1038.
  • 32
    Zeiher AM. Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 1996; 348 Suppl: s102.
  • 33
    Filer AD, Gardner-Medwin JM, Thambyrajah J, Raza K, Carruthers DM, Stevens RJ, et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003; 62: 1627.
  • 34
    Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009; 53: 212940.
  • 35
    Von Feldt JM. Premature atherosclerotic cardiovascular disease and systemic lupus erythematosus from bedside to bench. Bull NYU Hosp Jt Dis 2008; 66: 1847.
  • 36
    Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48: 130913.
  • 37
    Liu Y, Onouchi Z, Sakata K, Ikuta K. An experimental study on the role of smooth muscle cells in the pathogenesis of atherosclerosis of the coronary arteries. Nippon Shonika Gakkai Zasshi 1996; 100: 145358.
  • 38
    Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 46974.
  • 39
    Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment? Am J Med 1986; 80: 9259.
  • 40
    Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep 2004; 6: 4939.
  • 41
    Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 85965.
  • 42
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 2938.
  • 43
    Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009; 339: b2584.
  • 44
    Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335: 136.